Selected references - NK cells in immunotherapy
Utilizing the CliniMACS® Plus and CliniMACS Prodigy® Platform for NK cell manufacturing
Selected references - NK cells in immunotherapy
Natural killer (NK) cell and CAR NK cell-based immunotherapies show an enormous potential for the treatment of several diseases. The interest in the field keeps growing and so do the possibilities.
We have compiled a selection of influential papers and reviews showcasing the use of CliniMACS Instruments in the field of NK cell therapy and their wide range of clinical applications.
Clinical study results – Patient treatment with NK cell products
- Safety, efficacy, and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Marin, D. et al. (2024) Nat. Med. 30: 772–84. | Read article
- Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients
Ahmadvand, M. et al. (2023) BMC Cancer 23: 1090. | Read article
- Haploidentical natural killer cell therapy as an adjunct to stem cell transplantation for treatment of refractory acute myeloid leukemia
Kulkarni, U. et al. (2023) Cell Transplant. 32. | Read article
- Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
Shapiro, R. M. et al. (2022) J. Clin. Invest. 132: e154334. | Read article
- Sub-myeloablative second transplantations with haploidentical donors and post-transplant cyclophosphamide have limited anti-leukemic effects in pediatric patients
Epperly, R. et al. (2022) Transplant. Cell. Ther. 28: 262.e1–262.e.10. | Read article
- Long-term outcome after adoptive immunotherapy with natural killer cells: alloreactive NK cell dose still matters
Parisi, S. et al. (2022) Front. Immunol. 12: 804988. | Read article
- A phase I study to determine the maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors
Folashade, O. et al. (2022) Transplant. Cell Ther. 28: 250.e1–250.e8 | Read article
- Phase I trial of prophylactic donor-derived IL-2-activated NK cell infusion afterallogeneic hematopoietic stem cell transplantation from a matched sibling donor
Devillier, R. et al. (2021) Cancers 13: 2673. | Read article
- The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naive T cell depelted allogeneic stem cell transplantation
Gasior, M. et al. (2021) Transfusion 61: 1505–17. | Read article
- Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia
Berrien-Elliot, M. M. et al. (2020) Cancer Discov. 10: 1854–71. | Read article
- Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial
Nguyen, R. et al. (2020) J. Immunother. Cancer. 8: e000176. | Read article
- Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma
Tschan-Plessl, A. et al. (2020) Cytotherapy 23: 329–38. | Read article
Technical performance, NK cell functionality, and pre-clinical data
- Manufacturing of primary CAR NK cells in an automated system for the treatment of acute myeloid leukemia
Albinger, N. et al. (2024) Bone Marrow Transplant. 59: 489–95. | Read article
- Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia
De Jonge, P. K. J. D. et al. (2023) Cancer Immunol. Immunother. 72: 3323–35. | Read article
- Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
Haroun-Izquierdo, A. et al. (2022) J. Immunother. Cancer 10: e005577. | Read article
- Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy
Fernández, A. et al. (2021) Cancers 13: 577. | Read article
- Analysis of ex vivo expanded and activated clinical grade human NK cells after cryopreservation
Damodharan, S. N. et al. (2020) Cytotherapy 22: 450–7. | Read article
- Robust selections of various hematopoietic cell fractions on the CliniMACS Plus Instrument
Panch, A. R. et al. (2019) Clin. Hematol. Int. 1: 161–7. | Read article
- Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering.
Oberschmidt, O. et al. (2019) Hum. Gene Ther. Methods 30: 102–20. | Read article
- Clinical‐scale production of cGMP compliant CD3/CD19 cell‐depleted NK cells in the evolution of NK cell immunotherapy at a single institution
Williams, S. M. et al. (2018) Transfusion 58: 1458–67. | Read article
- Optimization of human NK cell manufacturing: Fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells
Klöß, S. et al. (2017) Hum. Gene Ther. 28: 897–913. | Read article
- Haploidentical natural killer cell therapy: Analysis of 205 Clinimacs procedures of CD3 depletion followed by CD56 selection
Tsang, K. S. et al. (2017) Cytotherapy 19: 47–8. | Read article